QuidelOrtho (QDEL)
(Delayed Data from NSDQ)
$29.96 USD
-0.05 (-0.17%)
Updated Jul 10, 2024 04:00 PM ET
After-Market: $29.89 -0.07 (-0.23%) 7:58 PM ET
5-Strong Sell of 5 5
A Value C Growth A Momentum A VGM
QuidelOrtho (QDEL) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$54.33 | $72.00 | $37.00 | 81.04% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for QuidelOrtho comes to $54.33. The forecasts range from a low of $37.00 to a high of $72.00. The average price target represents an increase of 81.04% from the last closing price of $30.01.
Analyst Price Targets (6 )
Broker Rating
QuidelOrtho currently has an average brokerage recommendation (ABR) of 3.29 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by seven brokerage firms. The current ABR compares to an ABR of 3.29 a month ago based on seven recommendations.
Of the seven recommendations deriving the current ABR, two are Buy, representing 28.57% of all recommendations. A month ago, Buy represented 28.57%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/QDEL.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 0 | 0 | 0 | 0 | 0 |
Buy | 2 | 2 | 2 | 2 | 2 |
Hold | 3 | 3 | 3 | 3 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 2 | 2 | 2 | 2 | 2 |
ABR | 3.29 | 3.29 | 3.29 | 3.29 | 3.29 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/9/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
3/4/2024 | UBS | John N Sourbeer | Not Available | Strong Sell |
2/14/2024 | Craig-Hallum | Alex Nowak | Strong Buy | Hold |
2/14/2024 | Raymond James | Andrew Cooper | Strong Buy | Moderate Buy |
2/14/2024 | William Blair | Andrew F Brackmann | Strong Buy | Hold |
12/11/2023 | Not Identified | Not Identified | Strong Buy | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 3.29 |
ABR (Last week) | 3.29 |
# of Recs in ABR | 7 |
Average Target Price | $54.33 |
LT Growth Rate | NA |
Industry | Medical - Products |
Industry Rank by ABR | 170 of 252 |
Current Quarter EPS Est: | -0.21 |